Table 1.

Summary of recent SGLT2i studies with effects on primary and secondary renal endpoints.

Trial	Drug	Kidney-related outcome	Effective kidney outcome
		Primary endpoint
DAPA-CKD (2020)	Dapagliflozin	Composite of decline in the eGFR of at least 50%, ESKD ,or death from renal or CV causes	HR: 0.61; 95% CI: 0.51–0.72
CREDENCE (2019)	Canagliflozin	Composite of ESKD outcomes, doubling SCr, or death from renal or CV causes	HR: 0.70; 95% CI: 0.59–0.82
		Secondary endpoint
VERTIS CV (2020)	Ertugliflozin	Composite of death from renal causes, KRT, or doubling of SCr	HR: 0.81; 95.8% CI, 0.63–1.04
EMPEROR-Reduced (2020)	Empagliflozin	Composite of KRT, sustained reduction eGFR ≥ 40%, sustained eGFR < 15mL/min per 1.73 m2 if baseline eGFR ≥ 30 mL/min per 1.73 m2, sustained eGFR < 10 mL/min per 1.73 m2 if baseline eGFR < 30 mL/min per 1.73 m2	HR: 0.50; 95% CI: 0.32–0.77
DECLARE-TIMI 58 (2019)	Dapagliflozin	Composite of ≥ 40% decrease in eGFR to < 60 mL/min per 1.73 m2, ESKD, death from CV or renal causes	HR: 0.76; 95% CI: 0.67–0.87
DAPA HF (2019)	Dapagliflozin	Composite of sustained decline in the eGFR ≥ 50%, ESKD or death from renal causes	HR: 0.71; 95% CI, 0.44–1.26
EMPA-REG OUTCOME (2016)	Empagliflozin	Incident or worsening nephropathy (progression to severely increased albuminuria, doubling of SCr, initiation of KRT, or renal death) and incident albuminuria	HR: 0.61; 95% CI: 0.53–0.70
CANVAS (2017)	Canagliflozin	Sustained 40% reduction in eGFR, initiation of KRT, or death from renal causes	HR: 0.60; 95% CI: 0.47–0.77